Browsing by Person Plöderl, Martin

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  

Showing results 1 to 20 of 22  next >
Issue DateTitleInvolved Person(s)
Jun-2019Antidepressiva wirken! Oder doch nicht?Plöderl, Martin; Hengartner, Michael Pascal
2019Comment on Osler et al : misinterpretation of pre‐post‐differences invalidate the authors’ conclusionsVolkmann, Constantin; Plöderl, Martin; Hengartner, Michael Pascal
2020Commentary to “antidepressants and suicidality : a re-analysis of the re-analysis”Plöderl, Martin; Hengartner, Michael Pascal; Bschor, Tom; Kaminski, Jakob André
25-Nov-2020Did the introduction and increased prescribing of antidepressants lead to changes in long-term trends of suicide rates?Amendola, Simone; Plöderl, Martin; Hengartner, Michael Pascal
17-Dec-2021Effect of the FDA black box suicidality warnings for antidepressants on suicide rates in the USA : signal or noise?Plöderl, Martin; Hengartner, Michael Pascal
2020Efficacy of new-generation antidepressants assessed with the Montgomery-Asberg depression rating scale, the gold standard clinician rating scale : a meta-analysis of randomised placebo-controlled trialsHengartner, Michael Pascal; Jakobsen, Janus C.; Sørensen, Anders; Plöderl, Martin
2021Estimates of the minimal important difference to evaluate the clinical significance of antidepressants in the acute treatment of moderate-to-severe depressionHengartner, Michael Pascal; Plöderl, Martin
Sep-2018False beliefs in academic psychiatry : the case of antidepressant drugsHengartner, Michael Pascal; Plöderl, Martin
2019Guidelines for the pharmacological acute treatment of major depression : conflicts with current evidence as demonstrated with the German S3-guidelinesPlöderl, Martin; Hengartner, Michael Pascal
8-Nov-2021Learning about the course of suicidal behavior but not about the effects of SSRIsPlöderl, Martin; Hengartner, Michael Pascal
24-Jun-2019Letter to the editor: newer-generation antidepressants and suicide risk in randomized controlled trials : a re-analysis of the FDA databaseHengartner, Michael Pascal; Plöderl, Martin
17-Nov-2020Moon and suicide : a true effect or a false-positive finding?Plöderl, Martin; Hengartner, Michael Pascal
2021Prophylactic effects or withdrawal reactions? : an analysis of time-to-event data from antidepressant relapse prevention trials submitted to the FDAHengartner, Michael Pascal; Plöderl, Martin
2019Reply to the letter to the editor : “newer-generation antidepressants and suicide risk : thoughts on Hengartner and Plöderl’s re-analysis”Hengartner, Michael Pascal; Plöderl, Martin
Jan-2020Sertraline in primary care : comments on the PANDA trialHengartner, Michael Pascal; Plöderl, Martin; Braillon, Alain; Jakobsen, Janus C.; Gluud, Christian
2018Starting two antidepressants to prevent suicide : a potentially dangerous recommendation?Hengartner, Michael Pascal; Plöderl, Martin
2018Statistically significant antidepressant-placebo differences on subjective symptom-rating scales do not prove that the drugs work : effect Size and method bias matter!Hengartner, Michael P.; Plöderl, Martin
2021Suicidality and other severe psychiatric events with duloxetine : re-analysis of safety data from a placebo-controlled trial for juvenile fibromyalgiaHengartner, Michael Pascal; Plöderl, Martin
2021Suicide risk with selective serotonin reuptake inhibitors and other new-generation antidepressants in adults: a systematic review and meta-analysis of observational studiesHengartner, Michael Pascal; Amendola, Simone; Kaminski, Jakob A.; Kindler, Simone; Bschor, Tom, et al
2022Suizidpräventive Effekte von Ketamin und EsketaminPlöderl, Martin; Hengartner, Michael P.; Volkmann, Constantin